Table 2.

Values for BP_ND estimated with independent ROI analysis for the regions where SPM showed that MP’s effects differed between groups for the measures taken during placebo (PL) and methylphenidate (MP), and for the difference between them (delta) for the controls (n = 19), for the cocaine abusers tested with exposure to neutral- and cocaine cue-videos (cohort #1, n = 24) and for the cocaine abusers tested with no video stimulation (cohort #2; n = 19) along with the effect size (Cohen’s d) for the within (row) and between comparisons (columns)

	Controls	COC abusers cohort #1	Effect size	COC abusers cohort #2	Effect size
Putamen PL	2.58 ± 0.24	2.46 ± 0.53		2.51 ± 0.41
Putamen MP	2.16 ± 0.30	2.36 ± 0.51		2.48 ± 0.50
Delta Putamen	− 0.42 ± 0.30	− 0.11 ± 0.28***	1.1	− 0.04 ± 0.32***	1.22
Effect size	1.4	NS		NS
VS PL	2.74 ± 0.49	2.33 ± 0.38**		2.15 ± 0.38***
VS MP	2.35 ± 0.42	2.33 ± 0.31		2.14 ± 0.40
Delta VS	− 0.39 ± 0.44	− 0.00 ± 0.28***	1.1	− 0.01 ± 0.35**	0.96
Effect size	0.89	NS		NS
BA 10 PL	1.04 ± 0.04	1.03 ± 0.06		1.04 ± 0.09
BA 10 MP	0.99 ± 0.10	1.04 ± 0.07		1.04 ± 0.07
Delta BA 10	− 0.05 ± 0.10	0.01 ± 0.05*	0.75	0.00 ± 0.07	0.54
Effect size	0.65	NS		NS

Abbreviations: BA, brodmann area; COC, cocaine; MP, methylphenidate; NS, non significant; PL, placebo; VS, ventral striatum.

Comparisons between controls and cocaine abusers correspond to post hoc t-tests

^*P < 0.05;

^**P < 0.005 and

^***P < 0.001.

The within-group comparison between PL and MP were only significant in the controls for putamen (P < 0.001), VS (P < 0.002) and brodmann area 10 (P < 0.05).